Becerra Could Use March-In Rights On Several Operation Warp Speed Contracts

By Ariel Cohen / December 9, 2020 at 6:43 PM
Xavier Becerra, President-elect Joe Biden’s nominee for HHS secretary, recently asked the federal government to use a controversial monopoly-busting mechanism to lower the cost of the COVID-19 drug remdesivir, and there are several COVID-19 drugs and vaccines that are susceptible to the government’s so-called march-in rights. The Trump administration did not use the march-in policy, but both Democratic and Republican attorneys general AGs as well as left-leaning policy experts want the Biden administration to consider it. Becerra’s position on remdesivir...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.